Semaglutide May Slow Biological Aging - What the Research Actually Shows
A new Nature Communications study found semaglutide slowed epigenetic aging markers by 9%. Here's what that means for the research community.
Research & News
Latest research findings, TGA updates, and community insights on GLP-1 peptides and research compounds in Australia.
Most Obesity Drugs Don't Improve Quality of Life, Says Major BMJ Review
A new BMJ network meta-analysis found most GLP-1 drugs cause weight loss but don't meaningfully improve quality of life or heart health. The nuance matters.
Why Vertex Just Spent $10 Billion on Oral Peptide Technology
Vertex's $10B Crinetics acquisition signals massive commercial confidence in oral peptide delivery. What it means for the research peptide space.
Wegovy Tablets Are Now on Sale in the UK - What It Means for Australia
Novo Nordisk's oral semaglutide pill hit UK pharmacy shelves on July 6. Boots is selling it from £79. Australia is still waiting.
Reta Is Everywhere - The $100M Grey Market for Retatrutide
Washington Post, CBS News and a crypto investigation all found unapproved retatrutide being sold openly. The underground market is worth $100 million.
Forget Weekly Injections - Novo Nordisk Is Building a Semaglutide Implant
Novo signed a deal with Vivani Medical to evaluate a tiny semaglutide implant that could last months. The delivery method wars are here.
FDA Scientists vs RFK Jr: The Battle Over Peptide Access Heats Up
FDA career scientists are pushing back against expanded peptide access ahead of a crucial July advisory committee meeting. Here's what's at stake for BPC-157, TB-500, and more.
Half of Peptide Users Don't Know What They're Taking
A new Hone Health survey found 50% of peptide users think their compounds are FDA-approved when they're not. Here's what the data actually shows.
Foundayo: The First Oral GLP-1 Joins Medicare's $50 Program
Eli Lilly's orforglipron pill, branded as Foundayo, became the first oral GLP-1 approved by the FDA. Now it's part of Medicare's new weight-loss drug program.
Retatrutide Expanded Access: Who Got the Unapproved Drug?
Eli Lilly gave one patient special FDA access to retatrutide before approval. The story has sparked a massive debate about access, equity, and the expanded access program.
Counterfeit Retatrutide Hospitalises Melbourne Patients - Victoria Issues Health Alert
Victoria's Chief Health Officer has issued a health alert after six cases of acute liver toxicity linked to counterfeit retatrutide products.
The Oral GLP-1 Race Just Got More Interesting
Corxel's CX11 oral obesity pill hit 11.5% weight loss in Phase 2 trials and is heading to Phase 3. The race for a needle-free GLP-1 is heating up.
GLP-1 Misuse Among Eating Disorder Patients: New Research
A JAMA Psychiatry study found 32% of people with eating disorders have used GLP-1 drugs, with 10% reporting misuse. Here's what the data shows.
WA Needle Exchanges Report Dramatic Rise in Peptide Use
Harm-reduction services in Western Australia say people accessing needles for peptide use has doubled in three years, with demographics shifting fast.
Novo Nordisk Hacked - What It Means for GLP-1 Supply Chains
Two hacking groups targeted Novo Nordisk and attempted multi-million dollar ransoms. Here is what the research community should know.
FDA Cracks Down on Telehealth Companies Selling Compounded GLP-1s
The FDA has issued warning letters to telehealth companies for false and misleading claims in their marketing of compounded GLP-1 weight loss drugs.
Medicare GLP-1 Bridge Program - $50 Weight-Loss Drugs from July 1
The US Medicare system will offer GLP-1 drugs for $50 from July 1. A temporary program that may not stay temporary.
Pfizer's $10 Billion Obesity Gamble: Inside the Metsera Pipeline
Pfizer spent big to enter the obesity race. New data from ADA 2026 shows whether that bet is paying off.
ADA 2026 Obesity Drug Showdown - Retatrutide Leads, Rivals Struggle to Stand Out
The ADA 2026 conference showed Lilly's retatrutide setting new standards while Pfizer and Roche face differentiation challenges.
AstraZeneca's Elecoglipron: A New Oral GLP-1 Enters Late-Stage Testing
AstraZeneca is pushing its oral GLP-1 pill elecoglipron into Phase 3 trials. Here's what the Phase 2 data showed.
ADA 2026: The Obesity Drug Landscape Is Getting Crowded
The American Diabetes Association meeting delivered major data on retatrutide, CagriSema, and the next wave of obesity treatments. Here's what matters.
The Peptide Wave: How Australia's Media is Covering the GLP-1 Revolution
Australian media outlets are increasingly covering the peptide and GLP-1 phenomenon. Here's what the recent reporting tells us.
TGA Compounding Rules in 2026: What's Changed for Research Compounds
The TGA has updated its compounding framework. Here's what researchers need to know about the current regulatory landscape.
Who Gets Access to GLP-1 Drugs? The Telehealth Gatekeeping Problem
Insurance companies are routing patients through telehealth platforms to manage obesity drug costs. Not everyone thinks that's a good idea.
GLP-1s and Cancer Risk: What the Latest Research Shows
New studies suggest GLP-1 drugs may reduce cancer risk in 6 out of 7 cancers studied. Here's what the research actually says.
Retatrutide Phase 3: What the Latest Trial Data Shows
Eli Lilly's triple agonist retatrutide continues to advance through Phase 3 trials. Here's what the latest data reveals.
Oral GLP-1 Agonists: The Quest for a Pill-Form Alternative
Injectable peptides dominate the GLP-1 landscape, but oral alternatives are advancing. Here's where the research stands.
Survodutide and Liver Fat: What the Research Shows
Boehringer Ingelheim's dual agonist survodutide is generating interest for its effects on liver fat metabolism.
Survodutide Phase 3: New Data Raises Questions About Competitiveness
Boehringer Ingelheim's survodutide faces scrutiny after new Phase 3 data. Here's what the latest results suggest.
The Growth of Australia's Peptide Research Community
Australian interest in peptide research is surging. Here's how the community is evolving and what's driving the growth.
CagriSema: The Combination Approach to Metabolic Research
Novo Nordisk's combination of semaglutide and cagrilintide represents a new approach to metabolic research. Here's what we know.
Getting Started with Peptide Research Literacy in Australia
A beginner-friendly guide to understanding peptide research, Australian regulations, and building research literacy as a community member.
Ozempic Shortage in Australia: Current Status & Research Alternatives
Current Ozempic supply situation in Australia, TGA shortage listings, and the research landscape for alternative GLP-1 compounds.
Retatrutide: The Triple Agonist Reshaping Metabolic Research
Retatrutide (LY3437943) activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data and what it means for metabolic research.
Navigating Australia's Peptide Regulatory Landscape
Understanding the TGA framework is essential for anyone interested in peptide research in Australia. Here's a practical guide.
GLP-1 and Weight Management: The Science Explained
GLP-1 receptor agonists have shown significant effects on weight management in clinical trials. Here's how the science works.
How to Read Peptide Research: A Methodology Guide
Understanding research methodology is essential for evaluating peptide studies. Here's a practical guide for the research community.